Sally Bridget Lawlor - Dec 1, 2025 Form 4 Insider Report for Quoin Pharmaceuticals, Ltd. (QNRX)

Role
Chief Financial Officer
Signature
/s/ Sally Bridget Lawlor
Stock symbol
QNRX
Transactions as of
Dec 1, 2025
Transactions value $
$0
Form type
4
Date filed
12/3/2025, 05:39 PM
Previous filing
Sep 8, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lawlor Sally Bridget Chief Financial Officer C/O QUOIN PHARMACEUTICALS LTD.,, 42127 PLEASANT FOREST COURT, ASHBURN /s/ Sally Bridget Lawlor 2025-12-03 0002084407

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction QNRX Share Option (Right to Buy) Award $0 +10.3K $0.00 10.3K Dec 1, 2025 ADS 10.3K $19.36 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.
F2 The option grant was approved by the Compensation Committee of the Board of Directors of the Issuer on December 1, 2025.
F3 The option vests in four annual installments with 20% vesting on each of December 1, 2026, 2027 and 2028 and 40% vesting on December 1, 2029.